Unilateral Bevacizumab for Bilateral Diabetic Macular Edema

This study has been completed.
Information provided by:
Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:
First received: July 3, 2007
Last updated: October 11, 2007
Last verified: October 2007
The endothelial growth factor (VEGF), has been implied in the genesis of diverse Neovascular disease. In the industrialized and developing countries, the main cause of blindness is the diabetic retinopathy. Bevacizumab (Avastin, genentech, Inc., San Francisco, California, the USA) is a drug.In the last years its use "off-label", in ophthalmology field, has become popular. This is due to its proven safeness and effectiveness for the treatment of diverse ocular diseases. A lot has been speculated about the systemic absorption of Bevacizumab. It is for that reason that the objective of this study is the systematic and random revision of the fellows eyes, of the patients programmed for the intravitreal administration of Bevacizumab, with bilateral macular edema. In such a way that the therapeutic value in the fellow eye of bevacizumab can be determined

Condition Intervention Phase
Diabetic Macular Edema
Diabetic Retinopathy
Drug: bevacizumab
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study.

Resource links provided by NLM:

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Retinal thickness [ Time Frame: Interventional ]

Secondary Outcome Measures:
  • Best corrected visual acuity

Estimated Enrollment: 13
Study Start Date: April 2007
Study Completion Date: October 2007
  Show Detailed Description


Ages Eligible for Study:   30 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient greater of 30 years old, with bilateral diffuse diabetic macular edema, with any degree of diabetic retinopathy that has been programmed for Bevacizumab intravitreal administration in one of both eyes.
  • Bilateral macular Thickening, measured by OCT of 225mm or bigger.
  • Pupil dilatation greater than 5mm.
  • Patient with no previous treatment for diabetic macular edema.

Exclusion Criteria:

  • Focal diabetic macular edema or macular edema of different etiology, besides diabetes. (uveitis, pseudophakic patients, vitreous-retinal traction, CRVO, BRVO, CSC).
  • Macular edema 3B patter, measured by OCT, according to the macular edema classification.
  • Medical history of severe thromboembolic events, uncontrolled arterial hypertension, transitory ischemic attacks, cardiac stroke, acute cerebral vascular event.
  • Pregnant women or breast feeding women
  • Know allergy to Bevacizumab
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00496405

Asociación para Evitar la Ceguera en Mexico
Mexico, DF, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Principal Investigator: Raul Velez-Montoya, MD Asociación para Evitar la Ceguera en Mexico
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00496405     History of Changes
Other Study ID Numbers: APEC 
Study First Received: July 3, 2007
Last Updated: October 11, 2007
Health Authority: Mexico: Ministry of Health

Keywords provided by Asociación para Evitar la Ceguera en México:
Vascular endothelial growth factor.
Retinal Thickness
Diabetic Macular Edema
Optical Coherent Tomography

Additional relevant MeSH terms:
Diabetic Retinopathy
Macular Edema
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Endocrine System Diseases
Eye Diseases
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Signs and Symptoms
Vascular Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016